TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Borg rating of perceived exertion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Healing rate at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication rate (anal incontinence)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to return to daily activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Impairments of visuo-spatial memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increased within search errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Impaired use of strategies on spatial working memory subtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of critical food safety hazards
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elevated-risk inspection ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Prostate Symptom Score Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient and Clinician Global Impressions of Improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Blood Tac concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tac dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: grade of hematuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: self-assessment score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Need for further imaging
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in surgical plans
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Failure load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subconjunctival hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of liver function tests (LFTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful application of suction electrode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD symptom change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRHR1 methylation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NR3C1 methylation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Salivary flow reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive fungal cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Power grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALS‐FRS‐r score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AOPPs levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FRAP exercise values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cobb angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of cardiac events
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of vascular endothelium function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct identification of affected eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in modified Sharp erosion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Erythrocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Menopausal symptoms improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma concentrations of advanced glycation end products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentrations of precursors of advanced lipoxidation end products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma omega-3 FA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: frequency and severity of symptoms of malabsorption
Endpoint domain: Adverse events/effects
Primary endpoint: preservation of appetite
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Satisfaction with implant overdentures vs conventional dentures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: remission of vertigo and nystagmus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Patient Activation Measure (PAM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Facial nerve weakness postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number and severity of vasomotor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in total breast area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in area of mammographic density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative analgesic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oscillations during standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean wear of enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean wear of dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total stroke odds ratio
Endpoint domain: Mortality/survival
Primary endpoint: Functional outcome after stroke
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: number of aggressive responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of sTfR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale‐Brown Obsessive Compulsive Scale (Y‐BOCS) score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician-rated total nasal symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-rated total nasal symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in intranasal eosinophil and basophil counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improved self-care in intervention group
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Avoidance of re-hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ESR reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in folate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in vitamin B12 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative incidence of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Discontinuation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: weight/age index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: weight/length index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean log reduction factor for bacterial skin flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Subjective reports of sleep disturbance
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Reduction in standardized anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stent thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with four or more CSBMs per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Constipation symptom score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Strength of fractured hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrist flexion/extension range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PF4/heparin antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of deep venous thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Median POS-frequency/week reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from POS during the 12-week treatment period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal inspiratory flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of nasal allergy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Home Fel d 1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean FEV1 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: airway responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: need for supplement bronchodilators
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tidal Volume (TV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Procedure completion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inadvertent dural puncture
Endpoint domain: Adverse events/effects
Primary endpoint: Appropriate level of anesthesia achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased antibiotic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pearl index for in-treatment pregnancies
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of amenorrhea and bleeding patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Normal blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response
Endpoint domain: Mortality/survival
Primary endpoint: Child SHSe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perivenous artifacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dystonic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Medication requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clearance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Social Responsiveness Scale-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: custom-made goal-based measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual VSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exhaled nitric oxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increased coughing
Endpoint domain: Adverse events/effects
Primary endpoint: WOMAC pain subscale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FLACC scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic improvement of joint pain and stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Inhibition of platelet MAO-B activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tolerability of rasagiline
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality rate associated with pHi levels
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of multiple organ system failure (MOSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in inflammatory markers (cytokines)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in reproductive hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Anger control measured by Provocation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma homocysteine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MBL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tolerability and safety profile
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-inflammatory effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardioprotective effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of active TB among patients considered free of active TB
Endpoint domain: Mortality/survival
Primary endpoint: back muscular endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: core muscular endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of foods with a high glycemic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Consumption of desserts and sweets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes of interdental spacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of NG patch for preterm labor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in diagnostic knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemostasis time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful hemostasis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radial artery occlusion
Endpoint domain: Adverse events/effects
Primary endpoint: totally effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pregnancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance in taking the kits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Kit return
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recurrence of signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearing of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute rejection episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sensory integration capabilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: balance and mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in wmFEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HDRS score decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactivation of HSV‐1 or VZV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Seroconversion and seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMTs of anti-HBs antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Induction of measurable levels of antibodies towards preS1 and/or preS2-antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: week 6 CES-D score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: smoking rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait velocity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance improvement (Berg Balance Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change of LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of a >or=25% decline in kidney function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Adjusted annualized least-square mean decline in estimated GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Completeness of data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Survival-without-morbidity at discharge
Endpoint domain: Mortality/survival
Primary endpoint: NDI at 2 years
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Vaccine response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prebooster antibody persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of dermatomes anaesthetized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intra‐operative and postoperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: rate of re-intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Deviation (MD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pattern Standard Deviation (PSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic precision (sensitivity and specificity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: virological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cost per avoided local recurrence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost per gained QALY
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Infusion requirements to maintain 95% twitch depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suturing time of the first fibroid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: fibroid volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence rate of intracerebral hemorrhage (ICH)
Endpoint domain: Mortality/survival
Primary endpoint: perceived appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: satisfaction with appearance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: attractiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: average daily pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global response assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: urgency episode frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak hip abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Intravenous narcotic use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention